ALX Oncology (ALXO) Revenue & Revenue Breakdown
ALX Oncology Revenue Highlights
00
ALX Oncology Revenue by Period
ALX Oncology Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | - | 100.00% |
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | -100.00% |
2020-12-31 | $1.18M | -75.35% |
2019-12-31 | $4.80M | 132.03% |
2018-12-31 | $2.07M | - |
ALX Oncology generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
ALX Oncology Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2025-06-30 | - | 100.00% |
2025-03-31 | - | -100.00% |
2024-12-31 | $868.00K | 100.00% |
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $2.48M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | -100.00% |
2020-12-31 | $1.18 | 100.00% |
2020-09-30 | - | -100.00% |
2020-06-30 | $527.00K | -19.54% |
2020-03-31 | $655.00K | -46.00% |
2019-12-31 | $1.21M | -3.42% |
2019-09-30 | $1.26M | -3.01% |
2019-06-30 | $1.29M | 25.48% |
2019-03-31 | $1.03M | - |
ALX Oncology generated - in revenue during Q2 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
ALX Oncology Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
GLUE | Monte Rosa Therapeutics | $75.62M | $84.93M |
KYMR | Kymera Therapeutics | $47.07M | $11.48M |
STOK | Stoke Therapeutics | $36.55M | $13.82M |
BCYC | Bicycle Therapeutics | $35.27M | $9.98M |
GBIO | Generation Bio | $19.89M | $765.00K |
IGMS | IGM Biosciences | $2.68M | $143.62M |
ALXO | ALX Oncology | - | - |
ANNX | Annexon | - | - |
NKTX | Nkarta | - | - |
TNYA | Tenaya Therapeutics | - | - |